Swiss regulators deny Apricus ED drug

Swiss authorities have thrown cold water on Apricus Biosciences' Vitaros, a topically-applied cream for erectile dysfunction. The product has been approved in Ireland, the Netherlands, Sweden and the U.K., but the company said Thursday that Swissmedic had turned down the drug. It is not that they have a problem with how the ED drug works. The regulators said the preclinical and clinical data were satisfactory and would likely support an approval. They have an issue with the targeted shelf life of the cold chain formulation and said it was not satisfactory for approval. Vitaros is the company's only approved product, and the San Diego, CA, drugmaker said it would appeal the decision. Release

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.